GPRC5D and Miyoshi myopathy: Talquetamab, an IgG4 antibody, targets G protein-coupled receptor family C group 5 member D (GPRC5D) and CD3 receptors and facilitates T-cell–mediated lysis of MM-specific cells, with a reported overall response rate (ORR) of 67-74% (10).